AlphaCore Capital LLC Acquires 2,877 Shares of AbbVie Inc. $ABBV

AlphaCore Capital LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 9.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,428 shares of the company’s stock after purchasing an additional 2,877 shares during the period. AlphaCore Capital LLC’s holdings in AbbVie were worth $7,638,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. DNB Asset Management AS raised its position in shares of AbbVie by 16.5% during the fourth quarter. DNB Asset Management AS now owns 575,107 shares of the company’s stock valued at $131,406,000 after buying an additional 81,312 shares during the last quarter. Lockheed Martin Investment Management Co. raised its position in shares of AbbVie by 12.0% during the fourth quarter. Lockheed Martin Investment Management Co. now owns 45,140 shares of the company’s stock valued at $10,314,000 after buying an additional 4,830 shares during the last quarter. Applied Finance Capital Management LLC raised its position in shares of AbbVie by 44.7% during the fourth quarter. Applied Finance Capital Management LLC now owns 29,894 shares of the company’s stock valued at $6,830,000 after buying an additional 9,239 shares during the last quarter. Northwestern Mutual Investment Management Company LLC raised its position in shares of AbbVie by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 56,472 shares of the company’s stock valued at $12,903,000 after buying an additional 167 shares during the last quarter. Finally, IMG Wealth Management Inc. raised its position in shares of AbbVie by 104.3% during the fourth quarter. IMG Wealth Management Inc. now owns 192 shares of the company’s stock valued at $44,000 after buying an additional 98 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Price Performance

ABBV opened at $210.54 on Friday. AbbVie Inc. has a one year low of $180.25 and a one year high of $244.81. The company’s 50 day simple moving average is $210.27 and its 200-day simple moving average is $220.10. The stock has a market capitalization of $371.97 billion, a P/E ratio of 103.71, a price-to-earnings-growth ratio of 0.73 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the firm earned $2.46 earnings per share. AbbVie’s revenue was up 12.4% compared to the same quarter last year. As a group, analysts anticipate that AbbVie Inc. will post 14.32 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date was Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 340.89%.

Analyst Ratings Changes

A number of brokerages have recently commented on ABBV. Canaccord Genuity Group upped their price objective on shares of AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Citigroup cut their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Piper Sandler upped their target price on shares of AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research note on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.